Excelsior Biopharma Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was TWD 325.329 million compared to TWD 386.045 million a year ago. Operating income was TWD 455,000 compared to TWD 16.017 million a year ago. Net loss was TWD 2.910 million compared to net income of TWD 10.743 million a year ago. Basic loss per share from continuing operations was TWD 0.06 compared to basic earnings per share from continuing operations of TWD 0.23 a year ago. Diluted loss per share from continuing operations was TWD 0.04 compared to diluted earnings per share from continuing operations of TWD 0.23 a year ago. For the half year, sales was TWD 670.686 million compared to TWD 731.983 million a year ago. Operating income was TWD 4.686 million compared to TWD 32.315 million a year ago. Net loss was TWD 339,000 compared to net income of TWD 23.359 million a year ago. Basic loss per share from continuing operations was TWD 0.01 compared to basic earnings per share from continuing operations of TWD 0.5 a year ago. Diluted earnings per share from continuing operations was TWD 0.02 compared to TWD 0.5 a year ago.